Vtv Therapeutics Stock Price, News & Analysis

Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for its drug azeliragon, aimed at treating glioblastoma, a highly aggressive brain tumor. This once-daily pill inhibits harmful interactions in the glioblastoma microenvironment. Clinical trials involving over 2000 individuals indicate that azeliragon is well tolerated. The Orphan Drug status provides Cantex with seven years of market exclusivity, tax credits, and other development advantages, highlighting the urgent need for new glioblastoma treatments.

vTv Therapeutics has appointed Steven Tuch as its new Chief Financial Officer, effective immediately. Tuch brings over 20 years of experience in financial planning and business development within the life sciences sector, previously leading Rallybio Corporation through a $92.7 million IPO. He will oversee the company's financial strategies as vTv prepares for Phase 3 trials of its lead candidate, TTP399, which has received breakthrough therapy designation. This appointment aims to enhance vTv's capital-raising efforts and support the advancement of innovative treatments for type 1 diabetes.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported its Q3 2022 financial results with a net loss of $4.3 million, or $0.05 per share, compared to a loss of $1.1 million in Q3 2021. The company is set to begin Phase 3 clinical trials for TTP399 in Q1 2023, with agreements in place with CinRx Pharma for $10 million in funding. Cash on hand was $15.3 million as of September 30, 2022. Research and development expenses increased to $3.1 million, primarily due to costs associated with TTP399. vTv aims to improve treatment for type 1 diabetes through these pivotal studies.

vTv Therapeutics Inc. (Nasdaq: VTVT) appointed Paul Sekhri as President and CEO, effective August 1, 2022. The company entered into agreements to raise $35 million by issuing stock to CinRx Pharma and G42 Investments, aimed at supporting clinical trials for TTP399, a treatment for type 1 diabetes. The company reported a net loss of $3.2 million for Q2 2022, compared to a loss of $0.6 million in the same period last year. Cash position improved to $17.9 million. vTv plans to initiate pivotal clinical trials for TTP399 in Q4 2022, engaging approximately 1,000 patients.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Paul Sekhri as President and CEO, effective August 1, 2022. Sekhri, who will also join the Board of Directors, comes at a pivotal time as the company prepares for Phase 3 studies of TTP399, an oral therapy for type 1 diabetes with Breakthrough Therapy designation from the FDA. Positive Phase 2 results showed significant improvements in HbA1c and reduced hypoglycemia rates. A $25 million investment from G42 will help fund the upcoming trials.

vTv Therapeutics (Nasdaq: VTVT) has entered into a $10 million investment agreement with CinPax, a subsidiary of CinRx Pharma. Under this deal, CinPax acquires over 4 million shares at approximately $2.41 each, with $6 million paid upfront and $4 million due by November 22, 2022. This investment will support vTv's Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. CinRx will leverage its expertise to assist in clinical trial oversight. vTv recently secured an additional $25 million from G42 Healthcare for the same purpose.

vTv Therapeutics (Nasdaq: VTVT) announced promising results of TTP399, a glucokinase activator for type 1 diabetes (T1D), showing it improves glycemia without increasing hypoglycemia risk. Findings from a JDRF-supported study indicated no cases of diabetic ketoacidosis (DKA) in TTP399-treated participants, while 42% of placebo subjects met DKA criteria. The study, published in Diabetes Obesity and Metabolism and presented at the ADA 2022 conference, supports TTP399's potential as a safe adjunct therapy for T1D.

On June 1, 2022, vTv Therapeutics (Nasdaq: VTVT) announced a $25 million investment from G42 Investments, acquiring 10,386,274 shares at $2.407 each. The investment partly funds Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. Additional shares worth $30 million may be issued if the FDA approves TTP399. This collaboration signifies a strategic partnership aimed at accelerating drug development and commercialization, leveraging G42's resources and expertise. TTP399 has shown promising results, including significant reductions in hypoglycemic episodes.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported Q1 2022 financial results, highlighting a revenue of $2 million, primarily due to increased transaction prices from licensing agreements. The company continues to focus on its lead program TTP399 for type 1 diabetes while pausing development on HPP737. As of March 31, 2022, cash reserves were $12.1 million. Net loss before non-controlling interest was $9.4 million, slightly down from $9.5 million in the previous quarter. The diluted net loss per share improved to ($0.10).